EA201890007A1 - Мультипептидная композиция - Google Patents

Мультипептидная композиция

Info

Publication number
EA201890007A1
EA201890007A1 EA201890007A EA201890007A EA201890007A1 EA 201890007 A1 EA201890007 A1 EA 201890007A1 EA 201890007 A EA201890007 A EA 201890007A EA 201890007 A EA201890007 A EA 201890007A EA 201890007 A1 EA201890007 A1 EA 201890007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
combination
composition
multipeptid
treatment
Prior art date
Application number
EA201890007A
Other languages
English (en)
Inventor
Марк Пикман
Original Assignee
Кинг'З Колледж Лондон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кинг'З Колледж Лондон filed Critical Кинг'З Колледж Лондон
Publication of EA201890007A1 publication Critical patent/EA201890007A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)

Abstract

В соответствии с настоящим изобретением предложена определенная комбинация пептидов. Указанная комбинация пептидов может входить в состав фармацевтически приемлемой композиции. Указанную комбинацию пептидов можно применять при терапии или профилактике сахарного диабета 1 типа (СД1). В настоящем изобретении также предложен способ диагностики или определения эффективности лечения, в указанном способе применяют указанную определенную комбинацию пептидов.
EA201890007A 2015-06-10 2016-06-10 Мультипептидная композиция EA201890007A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1510056.3A GB201510056D0 (en) 2015-06-10 2015-06-10 Multi-peptide composition
PCT/GB2016/051726 WO2016198887A1 (en) 2015-06-10 2016-06-10 Multi-peptide composition

Publications (1)

Publication Number Publication Date
EA201890007A1 true EA201890007A1 (ru) 2018-05-31

Family

ID=53785229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890007A EA201890007A1 (ru) 2015-06-10 2016-06-10 Мультипептидная композиция

Country Status (27)

Country Link
US (1) US11400131B2 (ru)
EP (1) EP3307298B1 (ru)
JP (1) JP6969790B2 (ru)
KR (1) KR20180023948A (ru)
CN (1) CN107896494B (ru)
AR (1) AR104947A1 (ru)
AU (1) AU2016275295B2 (ru)
BR (1) BR112017026537A2 (ru)
CA (1) CA2984957A1 (ru)
CL (1) CL2017003143A1 (ru)
CO (1) CO2017012986A2 (ru)
EA (1) EA201890007A1 (ru)
EC (1) ECSP18001655A (ru)
ES (1) ES2778630T3 (ru)
GB (1) GB201510056D0 (ru)
HK (1) HK1253094A1 (ru)
IL (1) IL256199A (ru)
MA (1) MA41668A1 (ru)
MX (1) MX2017015658A (ru)
PE (1) PE20180450A1 (ru)
PH (1) PH12017501918A1 (ru)
PL (1) PL3307298T3 (ru)
TN (1) TN2017000517A1 (ru)
TW (1) TW201712027A (ru)
UY (1) UY36722A (ru)
WO (1) WO2016198887A1 (ru)
ZA (1) ZA201707873B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986011B1 (en) * 1999-04-21 2015-02-11 Eisai Inc. Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
AU2002249895A1 (en) * 2001-01-05 2002-07-16 Joslin Diabetes Center, Inc. Autoantigen composition
GB0402129D0 (en) * 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
PL1709070T3 (pl) * 2004-01-30 2014-01-31 King S College London Peptydy do leczenia chorób autoimmunologicznych
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
ES2533566T3 (es) * 2006-12-29 2015-04-13 The Regents Of The University Of Colorado, A Body Corporate Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
EP2819689A1 (en) * 2012-03-01 2015-01-07 Yeda Research and Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides

Also Published As

Publication number Publication date
US11400131B2 (en) 2022-08-02
BR112017026537A2 (pt) 2019-11-12
GB201510056D0 (en) 2015-07-22
WO2016198887A1 (en) 2016-12-15
CO2017012986A2 (es) 2018-03-09
EP3307298A1 (en) 2018-04-18
AU2016275295B2 (en) 2021-12-09
HK1253094A1 (zh) 2019-06-06
TN2017000517A1 (en) 2019-04-12
MA41668A1 (fr) 2018-03-30
CN107896494A (zh) 2018-04-10
US20180221434A1 (en) 2018-08-09
ECSP18001655A (es) 2018-10-31
JP2018524301A (ja) 2018-08-30
PE20180450A1 (es) 2018-03-05
AR104947A1 (es) 2017-08-23
CA2984957A1 (en) 2016-12-15
PH12017501918A1 (en) 2018-03-19
EP3307298B1 (en) 2020-01-15
MX2017015658A (es) 2018-08-15
TW201712027A (zh) 2017-04-01
UY36722A (es) 2017-01-31
ES2778630T3 (es) 2020-08-11
CN107896494B (zh) 2021-09-03
CL2017003143A1 (es) 2018-05-18
IL256199A (en) 2018-02-28
AU2016275295A1 (en) 2017-12-07
PL3307298T3 (pl) 2020-06-29
JP6969790B2 (ja) 2021-11-24
ZA201707873B (en) 2019-05-29
KR20180023948A (ko) 2018-03-07

Similar Documents

Publication Publication Date Title
EA202190983A1 (ru) Новое антитело к с-kit
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
ECSP19077969A (es) Compuesto heterociclico
MX2023004973A (es) Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
EA201790552A1 (ru) Применение элсиглутида для лечения мукозита желудочно-кишечного тракта, включая индуцированную химиотерапией диарею
EA202090673A1 (ru) Стратификация генотипа при лечении и профилактике диабета
NZ733451A (en) Combination therapy for pulmonary hypertension